Search results
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
Reuters via AOL· 13 hours agoRinvoq helped 19.9% of patients simultaneously achieve near-complete skin clearance with a...
AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study By...
Investing.com· 8 hours agoAbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study
AbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1 (NYSE:ABBV)
Seeking Alpha· 11 hours agoAbbVie (ABBV) is set to report Q1 earnings results on April 26th. Analysts expect a profit of $2.26...
AbbVie announces LEVEL UP results in atopic dermatitis study By Investing.com
Investing.com· 13 hours agoThe study focused on adult and adolescent patients who had an inadequate response to systemic...
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
KFGO· 3 hours agoBy Patrick Wingrove and Amina Niasse (Reuters) - Cigna plans to make close copies of AbbVie's...
AbbVie (ABBV) to Release Quarterly Earnings on Friday
ETF DAILY NEWS· 23 hours agoAbbVie (NYSE:ABBV – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market opens on Friday, April 26th. Analysts expect the company to announce ...
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
Zacks via Yahoo Finance· 13 hours agoChicago, IL – April 25, 2024 – Today, Zacks Equity Research discusses Eli Lilly LLY, Novo Nordisk...
Buying the Dip in These 3 Undervalued Dividend Stocks
Motley Fool via Yahoo Finance· 3 days agoWe have seen a stock pullback here in April, and three of these high-quality dividend paying stocks...
REFILE-AbbVie's Rinvoq shows superiority to Regeneron's Dupixent in study
Reuters via Yahoo Finance· 13 hours ago(Corrects to remove extraneous text and to add Regeneron ticker symbol) April 25 (Reuters) - AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory ...
Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline
Zacks via Yahoo Finance· 6 days agoAbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings...